In the following video, Fool contributor Maxx Chatsko explains whether he thinks Gilead Sciences (GILD +1.14%) or Amgen (AMGN +2.27%) is the better buy. Both companies are trading at nearly identical market caps and have risen dramatically since the beginning of 2012 in anticipation of new blockbuster products. Both have robust pipelines stuffed full of potential at all levels of development. This is going to be a tough decision. If these companies are on your watchlist or if you're simply looking to add to a position, then you may want to use the current market volatility to your advantage.
Better Buy: Gilead or Amgen?
By Maxx Chatsko – Jun 25, 2013 at 3:00PM
NASDAQ: AMGN
Amgen
Market Cap
$161B
Today's Change
(2.27%) $6.64
Current Price
$298.64
Price as of October 31, 2025 at 3:58 PM ET
Both companies have pipelines full of potential. And the winner is...
About the Author
Maxx has been a contributor to Fool.com since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.